CEO and Chairman
Dr. Frost has been the CEO and Chairman of OPKO since March 2007. Previously, Dr. Frost served at Teva Pharmaceutical Industries, Limited ("Teva") as both Chairman of the Board and Vice Chairman. Dr. Frost served as Chairman of the Board of Directors and CEO of IVAX Corporation from 1987 until its acquisition by Teva in January 2006. He also served as chairman for Key Pharmaceuticals, Ladenburg Thalmann Financial Services and was a director of Continucare Corporation and Castle Brands, Inc. He was also a Governor and Co-Vice-Chairman of the American Stock Exchange.
Dr. Frost is a past chairman and currently serves as a member of the Board of Trustees of the University of Miami, the Shanghai Institute for Advanced Immunochemical Studies in China, and as a Trustee of the Miami Jewish ÄÐÈË¹¬µî for the Aged and the Mount Sinai Medical Center. He also serves as a member of the Executive Committee of the Phillip and Patricia Frost Museum of Science. He is a past member of the Board of Trustees of the Scripps Research Institute, the Board of Regents of The Smithsonian Institution, and the Skolkovo Foundation Scientific Advisory Council in Russia.
Dr. Frost is a director of Cocrystal Pharma, Inc., a publicly traded biotechnology company developing new treatments for viral diseases.
CTO and Vice Chairman
Dr. Hsiao has served as Vice-Chairman and Chief Technical Officer at OPKO since May 2007 and as a director since February 2007. Previously, Dr. Hsiao served as the Vice Chairman-Technical Affairs of IVAX, and as Chairman, CEO and President of IVAX Animal Health, IVAX's veterinary products subsidiary. She also served on the boards of Sorrento Therapeutics, PROLOR Biotech, SafeStitch Medical, and Neovasc, Inc.
Dr. Hsiao has served since 2008 as Chairman of the Board of Non-Invasive Monitoring Systems, Inc., a medical device company and was named Interim CEO of the company in 2012. Dr. Hsiao is also a director of TransEnterix, Inc., a medical device company, and Cocrystal Pharma, Inc.
Elias A. Zerhouni M.D.
President of ÄÐÈË¹¬µî and Vice Chairman
Dr. Elias A. Zerhouni M.D. has been the chairman and co-founder of ModeX therapeutics Inc., a start-up biotechnology company focused on multi specific-immune therapies for cancer and viral diseases, since November 2020. A physician scientist in Imaging and Biomedical Engineering, he served as President of global R&D and executive Vice President of Sanofi form 2010-2018, as Senior Fellow for global health research at the Bill and Melinda Gates foundation 2009-2010 and Presidential US envoy for science and technology 2009-2010. He was director of the US national Institutes of Health 2002-2008, Executive Vice Dean and Dean for research at the Johns Hopkins School of medicine 1996-2002, Professor of Radiology and Biomedical Engineering and chair of the department of Radiological sciences. Dr Zerhouni was elected to the National Academy of Medicine and to the National Academy of Engineering. He serves on the Board of the Lasker Foundation, the Foundation for NIH and the board of Research!America. He received the 2017 Scripps Executive of the year Award for the pharmaceutical industry and the French Legion of Honor in 2008. He has been a director of the publicly traded Danaher Corporation since 2009 to the present.
Executive Vice President, Administration
Mr. Rubin has served as Executive Vice President, Administration at OPKO since May 2007 and as a director since February 2007. Previously, Mr. Rubin served as the Senior Vice President, General Counsel and Secretary of IVAX from August 2001 until September 2006.
Mr. Rubin currently serves on the board of directors of Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates; Non-Invasive Monitoring Systems, Inc., a medical device company; Cocrystal Pharma, Inc., a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses; ChromaDex Corp., a science-based integrated nutraceutical company devoted to improving the way people age; Neovasc, Inc. a company developing and marketing medical specialty vascular devices, and Red Violet, Inc., leading analytics and information solutions provider.
Mr. Rubin previously served as a director of Castle Brands, Inc., Dreams, Inc., Safestitch Medical, Inc., Cogent, Inc., PROLOR Biotech, Inc., BioCardia, Inc., and VBI Vaccines, Inc.
Senior Vice President and CFO
Mr. Logal has served as OPKO's Sr. Vice President and Chief Financial Officer since March 2014, Vice President of Finance, Chief Accounting Officer and Treasurer from July 2012 until March 2014, and Director of Finance, Chief Accounting Officer and Treasurer from March 2007 until July 2012.
Previously, Mr. Logal served in senior management of Nabi Biopharmaceuticals, a publicly traded, biopharmaceutical company engaged in the development and commercialization of proprietary products. Mr. Logal held various positions of increasing responsibility at Nabi Biopharmaceuticals, last serving as Senior Director of Accounting and Reporting. Mr. Logal currently serves as chairman of the board of directors of Xenetics Biosciences, Inc., a clinical-stage biopharmaceutical company focused on discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics. He previously served on the board of directors of VBI Vaccines, Inc.
CEO of OPKO Renal
Dr. Bishop has served as CEO of the OPKO Renal Division since it was formed from OPKO's acquisition of Cytochroma Inc. on March 4, 2013. Dr. Bishop had served as President & CEO of Cytochroma since June 2006, bringing a wealth of management experience in the pharmaceutical industry across multiple disciplines including Research & Development, Regulatory Affairs, Operations, and Business Development. Dr. Bishop co-founded Proventiv Therapeutics, LLC in September 2005 where he served as President. Proventiv Therapeutics, LLC, and its lead drug, CTAP101 Capsules (approved by FDA in 2016 as "RayaldeeÂ® (calcifediol)", were acquired by Cytochroma in June 2006. From September 1987 to June 2005, Dr. Bishop held various senior management positions at Bone Care International, Inc. (NASDAQ: BCII), a public specialty pharmaceutical company focused on developing and commercializing vitamin D hormone therapies. Dr. Bishop's positions with Bone Care included President, CEO, Director, Executive Vice President of Research and Development, and Chief Scientific Officer. He was the first full-time employee in Bone Care, and he ran the Company from its inception until after the commercial launches of its first two products. Under Dr. Bishop's direction, Bone Care advanced a portfolio of proprietary vitamin D hormones and analogs to varying stages of development for secondary hyperparathyroidism (SHPT), metabolic bone disease, psoriasis and cancers of the prostate, breast, and colon. Dr. Bishop was responsible for the successful preparation and prosecution of three new drug applications that ultimately led to U.S. marketing approvals for a novel vitamin D drug, named doxercalciferol, for SHPT in dialysis patients (HectorolÂ® 2.5 mcg Capsules and HectorolÂ® Injection) and pre-dialysis patients (HectorolÂ® 0.5 mcg Capsules). Bone Care was acquired for $720 million by Genzyme Corporation in July 2005. Before joining Bone Care, Dr. Bishop held various management positions in the Health Care Division of the Procter & Gamble Company. Dr. Bishop completed a four-year National Institutes of Health Postdoctoral Fellowship in vitamin D Biochemistry at the University of Wisconsin-Madison and received his Ph.D. degree in Nutritional Biochemistry from Virginia Tech, after earning an undergraduate degree in Chemistry from the University of Virginia.
Gary J. Nabel
Chief Innovation Officer and Director
Dr. Gary J. Nabel M.D., Ph.D. has been the President and CEO of ModeX Therapeutics Inc., a start-up biotechnology company focused on multispecific immune therapies for cancer and viral diseases, since November 2020. He previously worked as Chief Scientific Officer and Senior Vice President of Sanofi from 2012-2020. A virologist and immunologist, Dr. Nabel served as founding director of NIHâ€™s Vaccine Research Center (VRC) and its leader for 14 years (1999-2012) working on vaccines and broadly neutralizing antibodies against HIV, influenza, SARS, Ebola, Chikungunya and Epstein-Barr virus. He was previously an investigator at the Howard Hughes Medical Institute at the University of Michigan (1987-1999). In recognition of his expertise at the forefront of virology, immunology, gene therapy, and molecular biology, Dr. Nabel was elected to the National Academy of Medicine and is a fellow of the American Association of Physicians, the American Academy of Arts Sciences, and the Geoffrey Beene Builders of Science Award from Research America. He worked previously as the board chair for the non-profit Keystone Symposia and currently serves on the board of Siga Technologies Inc., a publicly traded biotechnology company.
President of Transition Therapeutics
Dr. Cruz joined ÄÐÈË¹¬µî. in June 2017 as CEO, Transition Therapeutics Corp., ULC. Dr. Cruz was one of the founders and served as the Chairman and Chief Executive Officer of Transition Therapeutics, a NASDAQ and TSX publicly traded company. Transition's lead development programs are an oral compound for the treatment of Alzheimer' s disease for agitation and aggression and a GLP1 dual agonist for the treatment of type 2 diabetes partnered with Eli Lilly. Dr. Cruz was Co-founder of Angiotech Pharmaceuticals Inc. which developed the Taxol-coated stent for cardiovascular restenosis marketed by Boston Scientific. He served as Vice-President of Research and as a member of the Board of Directors. Dr. Cruz was a founding member and served as the Scientific Director and CEO of the Canadian Arthritis Network (CAN), a Network Centers of Excellence. Under his leadership, CAN raised approximately 30 Million dollars to support funding of research in the Network. Dr. Cruz has established numerous partnerships with Big Pharma, Biotech companies and the investment community in the Biotech Sector over the last 25 years. Dr. Cruz had a successful academic career from 1987 to 2008 with over 150 publications. He was a senior scientist at Mount Sinai Hospital and a Professor at the University of Toronto until 2008.
President, ÄÐÈË¹¬µî Iberoamerica
Hans Berner has been with OPKO since 2009. Since April of 2018, Hans has served as the President of ÄÐÈË¹¬µî Iberoamerica, which encompasses six business units located in five countries: Brazil, Chile, Mexico, Spain, and Uruguay. Hans has extensive experience in the Latin American pharmaceutical industry previously overseeing operations in Argentina, Mexico, and Uruguay as Corporative General Manager of Laboratorios ELEA S.A. Additionally, Hans worked as both the Latin American Regional Director for the IVAX Corporation and the General Manager of IVAX Argentina and IVAX Uruguay. Hans also has a background in business development and finance serving as Business Development Manager at Laboratorio Chile S.A. and Finance Manager at ING Bank Chile.
With over 15 years of teaching experience at various universities, Hans now holds a Professorship at the Pontificia Universidad CatÃ³lica de Chile instructing MBA students in the subjects of Competitive Strategy and M&A.
Hans earned his Commercial Engineering degree from the Universidad de Santiago de Chile before earning his MBA from the Business School of Pontificia Universidad CatÃ³lica Argentina. Subsequently, Hans entered post-graduate studies at Babson College in Entrepreneurship (Educators Santander Fellows). He also owns a Master in Clinical and Health Psychology from TECH Technological University, Spain.
Jane Pine Wood
CLO, BioReference Laboratories
Jane Pine Wood is a licensed and practicing attorney who oversees the company's Legal Department, with a focus on legal and regulatory compliance, corporate governance and corporate ethics. Jane joined BioReference after serving nearly three decades in private practice at McDonald Hopkins, LLC. She is a member of the American Health Lawyers Association, and has received the Association of Pathology Chairs' Friends of Pathology Award, American Society of Clinical Pathology Patients' Advocate Award, and is listed among Massachusetts Super Lawyers - Top 50 Female Lawyer Award. She holds her J.D. from Vanderbilt University School of Law and B.A. in History from Texas A&M University.
CEO, Eirgen Pharma
Damien Burke is the CEO of EirGen Pharma, a Waterford based pharmaceutical company specializing in the development and commercial supply of high potency pharmaceutical products including a number of oncology products. Damien has over 20 years of experience in the pharmaceutical industry and has held a number of senior leadership positions in supply chain, operations and business development. He has a MSc. in Supply Chain and Operational management from the University of Liverpool. Established in 2006, EirGen has grown rapidly and now exports products to over 40 countries worldwide including all of EU, U.S., Canada, Japan from its state of the art high containment facility. The facility is licensed by the Irish HPRA, FDA, and Japanese PMDA regulatory authorities.
President of API
Before joining OPKO, L. Arie Gutman founded FineTech Pharmaceuticals in 1990 which engaged in the development, manufacture, and marketing of specialty active pharmaceutical ingredients (APIs). Before its acquisition by OPKO in 2011, Finetech was previously acquired by Par Pharmaceuticals in 2002. Arie was then chosen to sit on the executive board. Arie also served as a Professor of Organic Chemistry at Technion - Israel Institute of Technology from 1992-2003, where he was recognized for his excellence in teaching and has been a Fellow of Churchill College, Cambridge since 1987. Arie has authored numerous publications and filed dozens of patents for his work. Arie earned his bachelors from Hebrew University, his M.Sc. from Technion - Israel Institute of Technology and his Ph.D. from Cambridge University.